Atara Biotherapeutics, Inc. (ATRA) EVP Christopher Haqq Sells 1,604 Shares

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Christopher Haqq sold 1,604 shares of Atara Biotherapeutics stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $13.36, for a total value of $21,429.44. Following the sale, the executive vice president now directly owns 344,134 shares in the company, valued at $4,597,630.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Christopher Haqq also recently made the following trade(s):

  • On Monday, October 16th, Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $14.35, for a total value of $86,100.00.
  • On Friday, September 15th, Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $15.30, for a total value of $91,800.00.

Atara Biotherapeutics, Inc. (NASDAQ ATRA) traded up $0.10 during trading hours on Friday, reaching $14.60. The company had a trading volume of 165,671 shares, compared to its average volume of 233,711. Atara Biotherapeutics, Inc. has a fifty-two week low of $11.80 and a fifty-two week high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.05). analysts anticipate that Atara Biotherapeutics, Inc. will post -4 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Atara Biotherapeutics, Inc. (ATRA) EVP Christopher Haqq Sells 1,604 Shares” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/11/19/atara-biotherapeutics-inc-atra-evp-christopher-haqq-sells-1604-shares.html.

A number of brokerages have recently issued reports on ATRA. Jefferies Group LLC reaffirmed a “buy” rating and set a $30.00 target price on shares of Atara Biotherapeutics in a research report on Thursday, October 5th. The Goldman Sachs Group, Inc. reaffirmed a “neutral” rating and set a $20.00 target price on shares of Atara Biotherapeutics in a research report on Friday, October 6th. Canaccord Genuity set a $47.00 target price on Atara Biotherapeutics and gave the stock a “buy” rating in a research report on Monday, August 7th. ValuEngine raised Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Zacks Investment Research lowered Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Monday, August 28th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $24.40.

A number of large investors have recently bought and sold shares of the stock. Eagle Asset Management Inc. grew its stake in Atara Biotherapeutics by 17.8% in the second quarter. Eagle Asset Management Inc. now owns 1,492,976 shares of the biotechnology company’s stock worth $20,901,000 after purchasing an additional 225,367 shares in the last quarter. Neuberger Berman Group LLC grew its stake in Atara Biotherapeutics by 15.2% in the third quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock worth $18,454,000 after purchasing an additional 147,061 shares in the last quarter. Vanguard Group Inc. grew its stake in Atara Biotherapeutics by 1.7% in the second quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock worth $11,842,000 after purchasing an additional 13,952 shares in the last quarter. Artal Group S.A. grew its stake in Atara Biotherapeutics by 20.0% in the third quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock worth $9,930,000 after purchasing an additional 100,000 shares in the last quarter. Finally, Northern Trust Corp grew its stake in Atara Biotherapeutics by 12.0% in the second quarter. Northern Trust Corp now owns 298,739 shares of the biotechnology company’s stock worth $4,183,000 after purchasing an additional 32,065 shares in the last quarter. Institutional investors and hedge funds own 82.95% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply